NEW YORK (TheStreet) --Since Donald Trump won Tuesday's election for President, both the healthcare and biotech sectors have responded positively. The SPDR Healthcare ETF (XLV) and the iShares NASDAQ Biotech ETF (IBB) were both climbing higher during afternoon trading on Thursday.
E Squared Asset Management health care portfolio manager Les Funtleyder joined CNBC's "Fast Money Halftime Report" this afternoon to comment on whether these rallies continue.
"Depends on what sector. I think biotech runs into a headwind because of higher interest rates, but pharma continues to go up because of repatriation and lots of other good things happening with pharma," Funtleyder said.
Names he's bullish on in the pharma space include Pfizer (PFE), Johnson & Johnson (JNJ), and United Health (UHS).
However, despite his bullish stance on pharma, he was much more cautious regarding biotech.
"Fade the rally. They're all going to come back and raise capital in the spring; you'll get your chance to buy small, and mid's probably sometime at the end of first quarter," he noted.
That said, there is one name within the biotech space he holds in higher regard.
"One that jumps out that we own and building a bigger position in is Gilead (GILD)," Funtleyder stated.
Noting the company will be able to repatriate a significant amount of capital from overseas, contingent on Trump following through on his promise to slash repatriation rates.
"I think next year will be a good year for them. They've got the ingredients; we're just looking for the recipe," Funtleyder said.